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Abstract
Glycogen phosphorylase is a key enzyme in glycogenolysis. Released with myocardial ischemia,
blood concentration of glycogen phosphorylase isoenzyme BB (GPBB) is a marker of acute
coronary syndromes. Pregnancy imposes metabolic stress, and preeclampsia is associated with
cardiac complications. However, plasma GPBB concentration during pregnancy is unknown. This
study was conducted to determine maternal plasma GPBB concentration in normal pregnancy and
in preeclampsia. Plasma samples from six groups (n=396) were studied: non-pregnant women and
pregnant women with normal term delivery, term preeclampsia, term small-for-gestational-age
neonates, preterm preeclampsia, and preterm small-for-gestational-age neonates. GPBB
concentration was measured with a specific immunoassay. Placental tissues (n=45) obtained from
pregnant women with preterm and term preeclampsia, spontaneous preterm delivery, and normal
term cases were analyzed for potential GPBB expression by immunoblotting. Median plasma
GPBB concentration was higher in pregnant women than in non-pregnant women (38.7 ng/ml
versus 9.2 ng/mL, P<0.001), which remained significant after adjusting for age, race, and parity.
Maternal plasma GPBB concentrations did not change throughout gestation. Preterm but not term
preeclampsia cases had higher median plasma GPBB concentration than gestational-age-matched
normal pregnancy cases (72.6 ng/ml versus 26.0 ng/ml, P=0.001). Small-for-gestational-age
neonates did not affect plasma GPBB concentration. GPBB was detected in the placenta and was
less abundant in preterm preeclampsia than in preterm delivery cases (P<0.01). There is
physiologic elevation of plasma GPBB concentration during pregnancy; an increase in maternal
plasma GPBB is a novel phenotype of preterm preeclampsia. It is strongly suggested that these
changes are attributed to GPBB of placental origin.
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Introduction
Glycogen phosphorylase (GP) is an essential enzyme in the regulation of glycogen
metabolism. It catalyzes and converts glycogen into glucose-1-phosphate in the first rate-
limiting step of glycogenolysis.1–5 Three different GP isoenzymes have been identified in
humans – GP isoenzyme LL (GPLL, liver), GP isoenzyme MM (GPMM, muscle), and GP
isoenzyme BB (GPBB, brain) – which have been named for the tissues in which they were
initially identified.1,2 Skeletal muscles solely contain GPMM; GPLL is present in all human
tissues except in the brain, heart, and skeletal muscles; and GPBB is mainly detected in the
brain but can also be found in high concentration in the heart muscle.1,2 When there is tissue
hypoxia and ischemia, glycogenolysis is initiated with the conversion of GP into its more
active, soluble, and cytoplasmic form by phosphorylase kinase.3 As cell membrane
permeability also increases during hypoxia, a high GP concentration gradient in the
sarcoplasmic reticulum compartment allows GP efflux into the bloodstream via the T-tubule
system.3 Based on the distribution of GPBB in the heart muscle and increased plasma
concentration of GP during ischemia and hypoxia, several studies have demonstrated that
plasma GPBB is a surrogate marker of acute coronary syndromes.3–6
Pregnant women experience dynamic and intense metabolic stress with increased cardiac
output in compliance with rising demands of the growing fetus and placenta.7 In addition,
during pregnancy, hypoxia plays a crucial role not only in normal placental and embryonic
development during the first trimester,8–10 but also in the development of adverse obstetric
outcomes including preeclampsia11–13 and fetal growth restriction (FGR).14 Furthermore,
maternal cardiac complications such as myocardial infarction and heart failure are more
frequent in cases with preeclampsia.15 However, the plasma concentrations of GPBB in
normal pregnancy and in pregnancy disorders have not been studied so far. We hypothesized
that there is a change in plasma GPBB concentration during pregnancy and especially in
association with preeclampsia.
The objective of this study was to determine the changes in maternal plasma GPBB
concentrations for normal pregnant women and women with preterm preeclampsia or term
preeclampsia.
Methods
Study Design
Plasma samples were collected from the following six groups classified according to the
clinical circumstances at the time of blood sampling: non-pregnant women (n=33), pregnant
women with a normal singleton pregnancy (n=151), patients with term preeclampsia (n=72),
patients with term small-for-gestational-age (SGA) neonates and no preeclampsia (n=38),
patients with preterm preeclampsia (n=74), and patients with preterm SGA neonates and no
preeclampsia (n=28). Three serial blood samples obtained during each trimester throughout
gestation (6–14 weeks, 15–24 weeks, and 37–42 weeks) were available in 32 of 151 normal
pregnant women. Preeclampsia was diagnosed according to the diagnostic criteria of the
American College of Obstetricians and Gynecologists:16 in the presence of hypertension
(elevated systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg at least
twice, 4 hours to 1 week apart, after the 20th week of gestation) and of proteinuria (≥300 mg
in a 24-hour urine collection, or 2 random urine specimens containing ≥1+ or more protein
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by dipstick or 1 dipstick measurement ≥2+ protein). SGA pregnancies included 1) those of
FGR fetuses detected by ultrasonography and confirmed SGA neonates after delivery in
cases of > 5 days of blood-sampling-to-delivery intervals, and 2) SGA neonates at the time
of delivery in cases of ≤ 5 days of intervals. The SGA neonate was defined when its birth
weight was below the 10th percentile for gestational age according to the reference range
proposed by Alexander et al,17 and FGR was diagnosed when the estimated fetal weight
proposed by Hadlock et al18 was below the 10th percentile for gestational age. A normal
pregnancy outcome was defined when patients met the following criteria: 1) no prior
abnormal medical and surgical conditions, 2) no obstetrical, maternal, or fetal complications
during pregnancy, and 3) delivery of a healthy neonate at term whose birth weight was
appropriate for gestational age (AGA) (>10th percentile and <90th percentile). Placental
tissues (n=45) were obtained from pregnant women with preterm preeclampsia (n=9),
preterm labor and preterm delivery (n=9), term preeclampsia (n=9), and normal term
delivery (n=18).
All women were enrolled at Hutzel Women’s Hospital in Detroit, Michigan, and provided
written informed consent for the collection and use of clinical data and biological materials.
Plasma and tissue samples from all patients were retrieved from the Bank of Biological
Materials of the Perinatology Research Branch, Eunice Kennedy Shriver National Institute
of Child Health and Human Development (NICHD), National Institutes of Health (NIH), U.
S. Department of Health and Human Services (DHHS). This study was conducted under the
ethical standards for human experimentation established in the Declaration of Helsinki. The
Institutional Review Boards of Wayne State University and the NICHD/NIH/DHHS
approved the collection and use of clinical data and biological materials for research
purposes.
Enzyme-linked Immunosorbent Assay (ELISA) for GPBB
Blood samples, collected in EDTA tubes, were centrifuged at 1,300xg for 10 min at 4°C.
The plasma samples were kept at −70°C until assay. Maternal plasma GPBB concentration
was measured with GPBB ELISA Kits (Diagenics SE, Essen, Germany), according to the
manufacturer’s instructions. The sensitivity of the assay was 1.463 ng/ml, and the
coefficients of intra-assay variation and inter-assay variation were 5.2% and 10.7%,
respectively.
Immunoblotting
Villous placental tissue samples were pooled from five different sampling sites. An equal
amount of placental villous tissues was taken from five sampling sites generated by a
systematic random sampling method. After trimming the chorionic plate and the basal plate,
the pooled samples were flash-frozen using liquid nitrogen and kept at −80°C until use.
Proteins were extracted from liquid nitrogen-pulverized chorionic villous tissue using a
radioimmunoprecipitation assay buffer (Sigma-Aldrich, St. Louis, MO) with a proteinase
inhibitor mixture (Roche, Basel, Switzerland). Protein lysates were subjected to 4–15%
SDS-PAGE gel (Bio-Rad, Hercules, CA), electrophoresed under reducing conditions, and
followed by electro-transfer onto polyvinylidene difluoride (PVDF) membranes (GE
Healthcare Bio-Sciences, Piscataway, NJ). Non-specific binding was blocked for 1 hour at
room temperature with 5% nonfat dry milk in TBS containing 0.1% Tween 20 (0.1% TBS-
T). After washing, membranes were incubated overnight at 4°C with primary antibodies
specific to GPBB (mouse anti-human; SC-81751) and HPRT (rabbit anti-human; SC-20975)
(1:200; Santa Cruz Biotechnology, Inc., Santa Cruz, CA). HRP-conjugated anti-mouse IgG
(7076) and anti-rabbit IgG (7074) (1:1,500; Cell Signaling Technology, Inc., Danvers, MA)
were used as secondary antibodies. Signals were detected using chemiluminescence
(ChemiGlow West Kit; Alpha Innotech Corporation, San Leandro, CA), and the
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densitometric analysis was performed using FluorChem SP densitometry (Alpha Innotech
Corporation).
Immunofluorescence Staining
For double-label immunofluorescence staining, 5-μm-thick frozen sections of the placenta
were used. These were fixed with 4% paraformaldehyde, permeabilized with 0.25% Triton
X-100, and incubated with 5% BSA in PBS for 30 min at room temperature. Tissue sections
were incubated with anti-GPBB (ab61036; 1:25; rabbit polyclonal; Abcam, Cambridge,
MA) and cytokeratin-7 (M7018; 1:1,000; mouse monoclonal, Dako, Carpinteria, CA) in 1%
BSA in PBS for 1 hour. Thereafter, the sections were incubated using Alexa Fluor® 488
donkey anti-rabbit IgG (A21206) and Alexa Fluor® 594 donkey anti-mouse IgG (A21203)
as secondary antibodies in 1% BSA for 30 min and mounted in ProLong Gold antifade
reagent with DAPI (Invitrogen, Carlsbad, CA). The stained sections were evaluated with a
Leica TCS SP5 spectral confocal system (Leica Microsystems, Wetzlar, Germany).
Statistical Analysis
Statistical analysis was performed using SPSS version 15.0 (SPSS Inc., Chicago, IL). For
continuous variables, after distributions were determined for normality using Kolmogorov-
Smirnov tests, the Kruskal-Wallis analysis of variance was used with the Mann-Whitney U
test or one-way ANOVA with post-hoc analysis. For categorical variables, proportions were
compared using the χ2 test or Fisher’s exact test. For related variables, the Friedman test
and the Wilcoxon signed rank test were performed to examine the change in maternal GPBB
concentrations throughout gestation. Medians and ranges or interquartiles were calculated
for continuous variables and frequencies and percentages were reported for categorical
variables. Analysis of covariance and logistic regression analysis were conducted for
comparison of maternal GPBB concentrations to adjust for maternal age, racial disparity,
parity, baby gender, and gestational age at blood sampling. All P values are 2-sided, and a
value of less than 0.05 is considered statistically significant.
Results
GPBB Plasma Concentration in Pregnancy and Preeclampsia
The analysis of plasma GPBB concentration in this study (Table 1 and Table 2) included
396 women. Table 1 shows the demographics and clinical characteristics of the study groups
of non-pregnant women and pregnant women with normal term delivery. Maternal age,
racial distribution, and parity were different between non-pregnant women and pregnant
women with normal term delivery (P<0.01, for each). Pregnant women with normal term
delivery included (1) 32 cases whose blood samples were drawn serially for the longitudinal
analysis, (2) 65 cases presenting with term in labor, (3) 25 cases presenting with term no
labor, and (4) 29 normal term delivery cases whose blood samples were collected before 37
weeks of gestation as preterm controls for preterm preeclampsia patients. Table 2 illustrates
the demographics and clinical characteristics of the study populations including cases with
preeclampsia or SGA neonates and their gestational age-matched controls both in term and
preterm gestations. There were significant differences in parity, gestational age at blood
sampling, gestational age at delivery, baby gender, the rates of SGA neonates, and Cesarean
delivery among groups both in term and preterm gestations (P<0.05, for each).
The median GPBB plasma concentration was significantly higher in pregnant women with a
normal pregnancy outcome (n=151) than in non-pregnant women (n=33) (median 38.7 ng/
ml, range 2.8–825.4 ng/ml vs. median 9.2 ng/ml, range 1.5–61.8 ng/ml, P<0.001), which
remained significant after adjusting for maternal age, race, and parity (Figure 1). In addition,
an analysis of plasma samples serially obtained during each trimester from 32 women with a
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normal pregnancy outcome, whose blood samples were drawn in the absence of labor,
demonstrated no differences in the maternal plasma GPBB concentration as a function of
advancing gestation (1st trimester: median 26.4 ng/ml, range 8.3–155.0 ng/ml; 2nd trimester:
median 39.5 ng/ml, range 6.0–205.5 ng/ml; and 3rd trimester: median 27.5 ng/ml, range 6.8–
88.5 ng/ml) (Figure 2).
Figure 3 displays the comparison of maternal plasma GPBB concentration according to the
presence or absence of labor at term because it was shown that labor itself is associated with
intermittent perfusion and oxidative stress of the placenta.19 The comparison was conducted
in patients at term with labor at the time of blood sampling (n=65) and those without labor at
the time of blood sampling (n=57: last drawn samples of cases for the longitudinal analysis
[n=32] and cases of additional term no labor at blood sampling [n=25]) (Table 1). There was
no statistically significant difference in maternal plasma GPBB concentration between
patients with and without labor (median 62.6 ng/ml, range 2.8–825.4 ng/ml vs. median 40.5
ng/ml, range 5.0–163.9 ng/ml, P=0.157).
Maternal plasma GPBB concentration was higher in preterm preeclampsia patients (n=74;
median 72.6 ng/ml, range 1.6–428.8 ng/ml) than in gestational-age-matched pregnant
women with a normal pregnancy outcome (n=33; median 26.0 ng/ml, range 6.8–205.5 ng/
ml) and in patients with preterm SGA neonates and no preeclampsia (n=28; median 15.9 ng/
ml, range 1.7–468.9 ng/ml) (P<0.01, for each), which remained statistically significant after
adjusting for maternal age, gestational age at blood draw, race, baby gender, and parity
(Figure 4A). Preterm SGA gestation without preeclampsia cases did not affect maternal
plasma GPBB concentration. In term pregnant women, there was no difference in the
maternal plasma GPBB concentration among preeclampsia cases (n=72; median 39.2 ng/ml,
range 2.7–311.9 ng/ml), SGA gestation and no preeclampsia cases (n=38; median 67.2 ng/
ml, range 3.3–158.4 ng/ml), and normal cases (n=122; median 45.2 ng/ml, range 2.8–825.4
ng/ml) (Figure 4B). In addition, preterm preeclampsia patients had a significantly higher
median plasma GPBB concentration than term preeclampsia patients (P<0.05).
Subgroup analysis was performed to determine the relationship between maternal plasma
GPBB concentration and the severity of preeclampsia. There were 82% (59/72) of term
preeclampsia patients and 96% (71/74) of preterm preeclampsia patients who had severe
symptoms and signs of preeclampsia based on the criteria of the American College of
Obstetricians and Gynecologists.16 There was no significant difference in the plasma GPBB
concentration according to the severity of preeclampsia both in term preeclampsia cases
(mild preeclampsia: median 21.0 ng/ml, range 6.1–147.9 ng/ml vs. severe preeclampsia:
median 39.5 ng/ml, range 2.7–311.9 ng/ml, P=0.959) and preterm preeclampsia cases (mild
preeclampsia: median 37.1 ng/ml, range 18.1–72.4 ng/ml vs. severe preeclampsia: median
72.8 ng/ml, range 1.6–428.8 ng/ml, P=0.331). However, severe preeclampsia cases at
preterm had a higher median plasma GPBB concentration than severe preeclampsia cases at
term (P<0.05). When subgroup analysis in the context of preeclampsia was conducted to
determine whether there is an additional effect of SGA birth on maternal plasma GPBB
concentration, preterm preeclampsia patients who delivered SGA neonates (n=37; median
63.0 ng/ml, range 1.6–263.7 ng/ml) and those who delivered AGA neonates (n=37; median
72.8 ng/ml, range 2.4–428.8 ng/ml) had higher median maternal plasma GPBB
concentrations than gestational-age-matched pregnant women with a normal pregnancy
outcome (n=33; median 26.0 ng/ml, range 6.8–205.5 ng/ml) (P<0.05, for each). However,
there was no difference in maternal plasma GPBB concentration between SGA neonates and
AGA neonates of preterm preeclampsia patients. There were also no differences in maternal
plasma GPBB concentration among term preeclampsia patients who delivered SGA
neonates (n=32; median 36.1 ng/ml, range 2.7–308.0 ng/ml) and AGA neonates (n=40;
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median 45.0 ng/ml, range 3.2–311.9 ng/ml) and gestational-age-matched pregnant women
with a normal pregnancy outcome (n=122; median 45.2 ng/ml, range 3.2–311.9 ng/ml).
Placental Expression of GPBB
The significant increase of GPBB concentration in normal pregnant women and particularly
in women with preterm preeclampsia, which is characterized by uteroplacental hypoxia, led
us to examine (1) whether GPBB is expressed in the placenta, and (2) whether there is a
difference in GPBB expression in the placenta according to the presence or absence of
preeclampsia and gestational age at delivery. When we conducted immunoblotting using the
placental protein lysates of 45 cases (Table S1, please see http://hyper.ahajournal.org),
GPBB was readily detected in the villous placenta of all cases (Figure 5A). Densitometric
analysis of immunoblotting data showed a significant decrease in the expression of GPBB in
preterm preeclampsia cases [n=9; median GPBB/HPRT ratio, 0.59 (range, 0.06–1.00)] than
in cases of preterm labor and delivery [n=9; median GPBB/HPRT ratio, 1.18 (range, 0.61–
2.64)] (P<0.01), while there was no difference in placental GPBB expression between term
preeclampsia cases [n=9; median GPBB/HPRT ratio, 1.10 (range, 0.62–1.54)] and normal
term delivery cases [n=18; median GPBB/HPRT ratio, 1.05 (range, 0.53–4.01)] (Figure 5B).
Accordingly, placental GPBB in preterm preeclampsia cases was less abundant than in term
preeclampsia cases (P<0.01). Labor itself did not change the GPBB expression in the
placentas of cases delivered at term, which was similar to the result in maternal plasma
GPBB concentration (Figure 5B). Immunofluorescence staining further demonstrated
distinct GPBB immunoreactivity in the syncytiotrophoblast and cytotrophoblast (Figure 5C).
Discussion
This study reports for the first time profiles of plasma GPBB concentration in normal
pregnancy and in pregnancy complicated with preeclampsia. The primary novel findings of
this study are: (1) there is a physiologic increase in plasma GPBB concentration during
pregnancy; (2) preterm but not term preeclampsia is characterized by a further increase in
plasma GPBB concentration; (3) GPBB is readily detected in the placenta and its abundance
is decreased in preterm preeclampsia cases; (4) SGA gestation does not affect plasma GPBB
concentration; and (5) there was no difference in maternal plasma GPBB concentration
between women with and without labor at term.
Normal tissues abundant in GPBB are the brain and the myocardium,1 and the placenta
turned out to be an additional source of the enzyme. While pregnancy is clearly a
physiological state, the median plasma GPBB concentration in normal pregnant women is
almost three times higher than the cut-off value (10 ng/ml) used for the diagnosis of acute
coronary syndromes in non-pregnant patients.5,6 Pregnancy remarkably alters cardiovascular
functions with increased cardiac output, but electrocardiographic changes are restricted to
only left-axis deviation, and there is no evidence that pregnancy increases the risk of
ischemic myocardial damage.7 Pregnancy can also change cerebrovascular blood flow, such
as the decrease in the mean blood flow of the middle and the posterior cerebral arteries, but
does not affect cerebrovascular autoregulation;20 and the blood-brain-barrier (BBB) remains
intact in healthy pregnant women.21 Therefore, it is less likely that the increase in the
plasma GPBB concentration during normal pregnancy is solely attributed to the GPBB
release from the heart or the brain. Instead, additional GPBB release from the placenta
would be a reasonable expectation.
Preeclampsia is a pregnancy-specific syndrome characterized by hypertension and
proteinuria, and it occurs in 5–8% of all pregnancies worldwide.22,23 Uteroplacental
hypoxia11,12 and anti-angiogenic conditions in maternal and fetal compartments24–27 are
reported as key steps for the occurrence of preeclampsia. It has been proposed that
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preeclampsia is a two-stage disorder: stage 1 (placental preeclampsia): abnormal
placentation leading to placental hypoxia, and stage 2 (maternal preeclampsia): maternal
symptoms of preeclampsia originating from placenta-derived circulating factors such as
soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sEng).28,29 Higher maternal
plasma GPBB concentration and lower placental GPBB expression in preterm preeclampsia
patients in the current study are very likely to be associated with uteroplacental hypoxia
leading to the conversion of GPBB into soluble form and to the release of placental GPBB
into the bloodstream. However, in contrast to normal pregnancy, increased GPBB released
from the heart and the brain would also be possible in patients with preeclampsia.
Hypertensive disorders in pregnancy are associated with the aberrations of cardiovascular
functions such as hyperdynamic ventricular function and low intravascular blood
volume.30,31 Moreover, Ladner et al have reported that essential hypertension and
preeclampsia are associated with the development of acute myocardial infarction during
pregnancy.32 Melchiorre et al also have reported that about 20% of patients with
preeclampsia at term show evident myocardial damage.33 In addition, increased BBB
permeability and brain edema are found in both preeclampsia and eclampsia patients.21,34
However, no patient of the current study was diagnosed with acute myocardial infarction or
brain damage during the index pregnancy.
Studies about preeclampsia have shown that there are significant differences in the
pathogenesis, blood biomarker profiles, and clinical presentations according to the
gestational age at disease onset.26,35–39 Preeclampsia developing before 37 weeks of
gestation (preterm preeclampsia) is a more severe and complicated maternal phenotype of
preeclampsia than that developing at term (term preeclampsia) in general.39 The risk of the
recurrence in later pregnancies,35 the long-term risk of mortality from the following
cardiovascular causes,36 the proportion of SGA neonates,37,38 and the concentrations of
maternal serum liver enzymes39 are higher in preterm preeclampsia patients than in term
preeclampsia patients. Huppertz recently proposed that these features largely comprise the
phenotype of early-onset but not late-onset preeclampsia.40 Our observation of a significant
increase in maternal plasma GPBB concentration in preterm preeclampsia, but not in term
preeclampsia, further supports the opinion that preeclampsia can be subclassified according
to the gestational age at disease onset.41
Pregnancies presenting SGA neonates and preeclampsia have been reported to share
common features of shallow placentation and uteroplacental insufficiency.42 However,
maternal manifestation of these conditions differs from each other, and some investigators
have proposed that they are biologically different disease entities.43 In the present study, an
additional effect of SGA birth on maternal GPBB concentration in preeclampsia cases was
not found, which suggests that the increased maternal GPBB concentration is mainly related
to preeclampsia. This finding was consistent with that from the analysis of GPBB
concentration according to SGA births among normotensive pregnant women. Although an
SGA gestation is one of the indicators for severity of preeclampsia,16 and commonly
associated with preeclampsia,38,44 an SGA gestation alone was less likely to affect maternal
GPBB concentration.
Previous studies of placental metabolism in preeclampsia have shown abnormalities in
glycogen metabolism.45–49 Bloxam et al demonstrated impaired glycolysis in the placentas
of women with preeclampsia by showing decreased concentrations of pyruvate and lactate
but not glycogen and glucose.46 Arkwright et al also have shown that glycogen content is
increased in the syncytiotrophoblast of preeclampsia cases, which was accompanied by 16-
fold and 3-fold increases of glycogen synthase content and glycogen phosphorylase
activity.47 Increased placental glycogen phosphorylase activity in preeclampsia cases is
quite consistent with our observation that release of GPBB is increased in pregnant women
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with preeclampsia, which would lead to a higher plasma concentration of GPBB and less
abundance in placental GPBB.
There are limitations in our study. As postpartum blood samples were unavailable, maternal
GPBB concentration during the postpartum period could not be examined. The change in
GPBB concentration after delivery would be a key piece of data in support of our hypothesis
that increased GPBB concentration during pregnancy originates from placental tissue.
Another limitation is that the blood samples and placental samples were not obtained from
the same pregnant women and the analysis using the blood and placental samples from the
same pregnant women would have been more relevant for the determination of placental
origin of peripheral blood GPBB, although it was not feasible for us. In this study, there
were differences of racial distribution and parity for each of the analyses such as (1) non-
pregnant women vs. pregnant women with a normal pregnancy, (2) preeclampsia vs. SGA
gestation vs. controls in preterm gestation, and (3) preeclampsia vs. SGA gestation vs.
controls in term gestation. Although the differences in plasma GPBB concentration
remained significant after adjusting for these confounding factors, future studies designed on
a large scale are needed to address this issue.
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Perspectives
Maternal plasma GPBB concentration is increased during pregnancy, and its robust
increase is a novel phenotype of preterm preeclampsia. The findings herein strongly
suggest that maternal plasma GPBB can be a useful marker in the detection of early-onset
(preterm) preeclampsia. Uteroplacental hypoxia precedes the clinical symptoms of
preeclampsia,28,29 and a future study on the predictive value of plasma GPBB
concentration as a marker of preeclampsia or other obstetric complications, such as fetal
death in asymptomatic pregnant women (i.e., during the mid-trimester), will be
necessary.
Lee et al. Page 11
Hypertension. Author manuscript; available in PMC 2013 February 01.
$watermark-text
$watermark-text
$watermark-text
Figure 1.
Plasma GPBB concentration in pregnant women. Median GPBB plasma concentration was
higher in pregnant women with a normal pregnancy outcome (n=151) than in non-pregnant
women (n=33) (P<0.001). Plasma GPBB concentrations were shown as median and
interquartile ranges.
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Figure 2.
Maternal plasma GPBB concentration as a function of gestational age. There was no
difference in the maternal plasma GPBB concentration as a function of advancing gestation.
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Figure 3.
Comparison of maternal plasma GPBB concentration according to the presence or absence
of labor. Maternal plasma GPBB concentration tended to be higher in patients in labor at
term (n=65) than in those not in labor at term (n=57), but the difference was not statistically
significant (P=0.157). Maternal plasma GPBB concentrations were shown as median and
interquartile ranges.
TNL: term not in labor, TIL: term in labor
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Figure 4.
Comparison of maternal plasma GPBB concentration according to preeclampsia and small-
for-gestational-age (SGA) neonates in preterm and term gestations. A, Maternal plasma
GPBB concentration was higher in preterm preeclampsia patients (n=74) than in gestational-
age-matched pregnant women with a normal pregnancy outcome (n=33) (P=0.001), while
there was no difference between patients with preterm SGA neonates and no preeclampsia
(n=28) and preterm controls. B, There was no difference in the maternal plasma GPBB
concentration among normal term cases (n=122), term preeclampsia cases (n=72), and
patients with term SGA neonates and no preeclampsia (n=38). Maternal plasma GPBB
concentrations were shown as median and interquartile ranges.
SGA, small-for-gestational-age
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Figure 5.
Placental expression of GPBB. A, GPBB was readily detected in the villous placenta of all
cases with immunoblotting. B, Placental GPBB was less abundant in preterm preeclampsia
cases (n=9) than in preterm labor and delivery cases (n=9), in term preeclampsia cases
(n=9), and in normal term delivery cases (n=18) (P<0.01, for each) as shown by
densitometric analysis. C, Distinct GPBB immunoreactivity in the syncytiotrophoblast and
villous cytotrophoblasts of a representative case of normal term delivery at 40 weeks. GPBB
expression is observed in the syncytiotrophoblast and villous cytotrophoblasts.
TNL: term not in labor, TIL: term in labor, PE: preeclampsia, PTL: preterm labor.
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